Complications, Adverse Drug Events, High Costs, and Disparities in Multisystem Inflammatory Syndrome in Children vs COVID-19 – PubMed

In this cross-sectional study, MIS-C was more common and severe than previously reported, with more racial disparities in outcomes than were seen in patients with COVID-19. The findings of this study suggest that relying on mean outcomes for MIS-C from past studies can be misleading …

Study Also Finds Underreporting of Severe Effects of COVID-19 in Children

Multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition that causes severe inflammation of multiple organ systems, was vastly underreported following COVID-19 infection in children, a new AHRQ study has found. In the study, published in JAMA Network Open, researchers used AHRQ’s Healthcare Cost and Utilization Project data to determine that for every five COVID-19 hospitalizations among children, there was one additional hospitalization for MIS-C. The analysis showed MIS-C was more common and severe than initially reported, and with more racial disparities than with COVID-19. Since deaths from MIS-C increase with the number of organ systems affected, researchers concluded that future efforts should focus on how to prevent MIS-C from progressing to multiple organ system dysfunction. Access the abstract.

Source: Complications, Adverse Drug Events, High Costs, and Disparities in Multisystem Inflammatory Syndrome in Children vs COVID-19 – PubMed

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.